These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8088366)

  • 21. Expression, purification and crystallization of human 5-lipoxygenase-activating protein with leukotriene-biosynthesis inhibitors.
    Xu S; McKeever BM; Wisniewski D; Miller DK; Spencer RH; Chu L; Ujjainwalla F; Yamin TT; Evans JF; Becker JW; Ferguson AD
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Dec; 63(Pt 12):1054-7. PubMed ID: 18084092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors.
    Vickers PJ; Adam M; Charleson S; Abramovitz M; O'Neill G; Mancini JA
    J Lipid Mediat; 1993; 6(1-3):31-42. PubMed ID: 8357989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linoleic acid peroxidation by Solanum tuberosum lipoxygenase was activated in the presence of human 5-lipoxygenase-activating protein.
    Battu S; Moalic S; Rigaud M; Beneytout JL
    Biochim Biophys Acta; 1998 Jun; 1392(2-3):340-50. PubMed ID: 9630716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.
    Gupta N; Nicholson DW; Ford-Hutchinson AW
    Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of 5-lipoxygenase and biosynthesis of leukotriene B4 in human monomorphonuclear leukocytes.
    Claesson HE; Jakobsson PJ; Steinhilber D; Odlander B; Samuelsson B
    J Lipid Mediat; 1993; 6(1-3):15-22. PubMed ID: 8395238
    [No Abstract]   [Full Text] [Related]  

  • 26. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly.
    Garscha U; Voelker S; Pace S; Gerstmeier J; Emini B; Liening S; Rossi A; Weinigel C; Rummler S; Schubert US; Scriba GK; Çelikoğlu E; Çalışkan B; Banoglu E; Sautebin L; Werz O
    Biochem Pharmacol; 2016 Nov; 119():17-26. PubMed ID: 27592027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatty acid binding proteins stabilize leukotriene A4: competition with arachidonic acid but not other lipoxygenase products.
    Zimmer JS; Dyckes DF; Bernlohr DA; Murphy RC
    J Lipid Res; 2004 Nov; 45(11):2138-44. PubMed ID: 15342681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.
    Stock N; Baccei C; Bain G; Chapman C; Correa L; Darlington J; King C; Lee C; Lorrain DS; Prodanovich P; Santini A; Schaab K; Evans JF; Hutchinson JH; Prasit P
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4598-601. PubMed ID: 20566292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 12-hydroxy- and 12-hydroperoxy-5,8,10,14-eicosatetraenoic acids on the synthesis of 5-hydroxy-6,8,11,14-eicosatetraenoic acid and leukotriene B4 in human blood leukocytes.
    Maclouf J; Fruteau de Laclos B; Borgeat P
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():159-62. PubMed ID: 6221520
    [No Abstract]   [Full Text] [Related]  

  • 30. 5-Lipoxygenase-activating protein (FLAP).
    Vickers PJ
    J Lipid Mediat Cell Signal; 1995 Oct; 12(2-3):185-94. PubMed ID: 8777565
    [No Abstract]   [Full Text] [Related]  

  • 31. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.
    Stock N; Baccei C; Bain G; Broadhead A; Chapman C; Darlington J; King C; Lee C; Li Y; Lorrain DS; Prodanovich P; Rong H; Santini A; Zunic J; Evans JF; Hutchinson JH; Prasit P
    Bioorg Med Chem Lett; 2010 Jan; 20(1):213-7. PubMed ID: 19914828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.
    Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich PP; Darlington JV; Stock NS; Zunic J; King CD; Lee C; Baccei CS; Stearns B; Roppe J; Hutchinson JH; Prasit P; Evans JF
    Eur J Pharmacol; 2010 Aug; 640(1-3):211-8. PubMed ID: 20519143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of indolylalkoxyiminoalkylcarboxylates as leukotriene biosynthesis inhibitors.
    Kolasa T; Bhatia P; Brooks CD; Hulkower KI; Bouska JB; Harris RR; Bell RL
    Bioorg Med Chem; 1997 Mar; 5(3):507-14. PubMed ID: 9113329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increases in 5-lipoxygenase activating protein expression account for enhanced capacity for 5-lipoxygenase metabolism that accompanies differentiation of peripheral blood monocytes into alveolar macrophages.
    Coffey MJ; Wilcoxen SE; Peters-Golden M
    Am J Respir Cell Mol Biol; 1994 Aug; 11(2):153-8. PubMed ID: 8049076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific high affinity binding of lipoxygenase metabolites of arachidonic acid by liver fatty acid binding protein.
    Raza H; Pongubala JR; Sorof S
    Biochem Biophys Res Commun; 1989 Jun; 161(2):448-55. PubMed ID: 2500117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FLAP: a novel drug target for inhibiting the synthesis of leukotrienes.
    Ford-Hutchinson AW
    Trends Pharmacol Sci; 1991 Feb; 12(2):68-70. PubMed ID: 2024291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids.
    Spokas EG; Rokach J; Wong PY
    Methods Mol Biol; 1999; 120():213-47. PubMed ID: 10343320
    [No Abstract]   [Full Text] [Related]  

  • 38. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.
    Fischer L; Hornig M; Pergola C; Meindl N; Franke L; Tanrikulu Y; Dodt G; Schneider G; Steinhilber D; Werz O
    Br J Pharmacol; 2007 Oct; 152(4):471-80. PubMed ID: 17704828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of the production and action of leukotrienes by MK-571 and MK-886.
    Ford-Hutchinson AW
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():9-16. PubMed ID: 1847788
    [No Abstract]   [Full Text] [Related]  

  • 40. Chronic leukotriene inhibition in the rat fails to modify the toxicological effects of a cyclooxygenase inhibitor.
    Ford-Hutchinson AW; Tagari P; Ching SV; Anderson CA; Coleman JB; Peter CP
    Can J Physiol Pharmacol; 1993; 71(10-11):806-10. PubMed ID: 8143238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.